Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 12 of 290 for:    "Glomerulonephritis"

Eculizumab in Primary MPGN (EAGLE)

This study is ongoing, but not recruiting participants.
Alexion Pharma Italy s.r.l.
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research Identifier:
First received: March 17, 2014
Last updated: April 12, 2016
Last verified: April 2016
Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative complement pathway and familial forms for all types of MPGN have been reported suggesting that genetic abnormalities may play a predisposing role to the disease. In recent case reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex ,is a safe and effective therapy.

Condition Intervention Phase
Membranoproliferative Glomerulonephritis
Drug: Eculizumab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Mario Negri Institute for Pharmacological Research:

Primary Outcome Measures:
  • 24hours proteinuria [ Time Frame: Changes from baseline at week 1,12,24,36,48 and 72. ]

Secondary Outcome Measures:
  • Terminal complement complex (sC5b-9) levels [ Time Frame: Changes from baseline at 1,2, 3, 4,12,24,36,48,52,56,60 and 72 week. ]
  • Glomerular filtration rate (GFR) measured by iohexol plasma clearance and estimated. [ Time Frame: Changes from Baseline at 1,24, 48 and 72 week. ]
  • Time to disease progression. [ Time Frame: Up 72 week. ]

Other Outcome Measures:
  • Number of participants with Adverse Events as a measure of safety. [ Time Frame: Participants will be followed for the duration of the study, an expected average of 72 weeks ]

Estimated Enrollment: 10
Study Start Date: March 2014
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eculizumab
Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
Drug: Eculizumab
Other Name: Soliris


Ages Eligible for Study:   up to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy-proven primary MPGN
  • Creatinine clearance >20 ml/min per 1.73m2
  • 24-hour proteinuria persistently exceeding 3,5g in adults or exceeding 40mg/h/m2 in children (or exceeding 2mg protein/mg creatinine in children spot urine samples)
  • Persistently low C3 levels in at least two consecutive evaluations
  • Persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive evaluations
  • Written informed consent (by parents or tutors if underage)

Exclusion Criteria:

  • Age ≥75 years
  • Secondary MPGN (evidence of infection, immunological disease including vasculitis, systemic diseases and proliferative disorders)
  • Evidence at kidney biopsy evaluation of severe chronic histological changes that very unlikely could benefit of eculizumab therapy
  • Concomitant steroid or immunosuppressive therapy for immuno-mediated disease
  • Pregnancy or lactating
  • Childbearing potential without effective contraception
  • Any clinically relevant condition that might affect completion of the study participation and/or confound study results
  • Inability to understand the potential risks and benefits of the study
  • Legal incapacity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02093533

Ospedale Pediatrico "Giovanni XXIII" - U:O Nefrologia
Bari, BA, Italy
A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò
Bergamo, BG, Italy
Policlinico Sant'Orsola -Malpighi - U.O.S. Nefrologia e dialisi pediatrica
Bologna, BO, Italy
Policlinico "G.Martino" - U.O. Nefrologia e Dialisi
Messina, ME, Italy
Policlinico Universitario di Padova - U.O. Nefrologia Pediatrica
Padova, PD, Italy
Ospedale Centrale
Bolzano, Italy, 39100
Policlinico "Federico II" - U.O. Nefrologia
Napoli, Italy
Ospedale degli Infermi - U.O. Nefrologia e Dialisi
Rimini, Italy
C.I. Columbus-Università Cattolica del S.Cuore - UOC Nefrologia e Dialisi
Roma, Italy
Ospedale Pediatrico "Bambin Gesù" - U.O. Nefrologia
Roma, Italy
Presidio Ospedaliero O.I.R.M. "Sant'Anna" - U.O. Nefrologia
Torino, Italy
Ospedale "Santa Chiara" - U.O. Nefrologia
Trento, Italy
Ospedale Cà Foncello - U.O. Nefrologia
Treviso, Italy
Sponsors and Collaborators
Mario Negri Institute for Pharmacological Research
Alexion Pharma Italy s.r.l.
  More Information

Responsible Party: Mario Negri Institute for Pharmacological Research Identifier: NCT02093533     History of Changes
Other Study ID Numbers: EAGLE
2013-003826-10 ( EudraCT Number )
Study First Received: March 17, 2014
Last Updated: April 12, 2016

Keywords provided by Mario Negri Institute for Pharmacological Research:
Membranoproliferative glomerulonephritis
Nephrotic syndrome
Alternative complement pathway
Complement inhibition

Additional relevant MeSH terms:
Glomerulonephritis, Membranoproliferative
Kidney Diseases
Urologic Diseases
Immune System Diseases processed this record on April 27, 2017